Inclusion Criteria:

          -  Must voluntarily sign an ICF; and must be able to meet all study requirements

          -  For escalation, subjects must have a pathologically confirmed diagnosis of PPV-MF,
             PETMF, or PMF as per the EHA or WHO diagnostic criteria (note that all diagnoses must
             include the presence of at least Grade 1 marrow fibrosis according to the European
             Consensus on Grading of BM Fibrosis as well as int-1, int-2, or high risk disease
             according to the IWG-MRT Dynamic IPSS; Patients with PV may enter the trial if they
             meet the labeled indication for ruxolitinib (eg hydroxyurea resistant or refractory);

               -  Escalation Stage 1 patients: who have not achieved normalization of splenomegaly,
                  symptomology, or blood counts with at least 8 weeks therapy with a steady dose of
                  ruxolitinib

               -  Escalation Stage 2: patients who have not yet received therapy with any JAK-STAT
                  inhibitory agents or patients on at least 8 weeks of a steady dose of
                  ruxolitinib; patients with exposure to other JAK-STAT inhibitory agents are not
                  eligible. After discussion with the study chair or designee, patients with
                  suboptimal response on at least 8 weeks of a steady dose of ruxolitinib may be
                  allowed to de-escalate ruxolitinib therapy in order to enter a safety cohort
                  which is enrolling patients at a lower dose; patients must receive the lower dose
                  of ruxolitinib for at least 7 consecutive days without event before adding
                  TGR-1202. If the patient completed screening evaluations including bone marrow
                  biopsy/aspirate prior to ruxolitinib de-escalation, it need not be repeated after
                  de-escalation provided that all evaluations occurred within 28 days prior to the
                  first dose of TGR-1202.

          -  For expansion,

               -  subjects may have a pathologically confirmed diagnosis of MF or PV as noted above
                  in #2. There are also two expansion cohorts for patients with MDS/MPN (CMML,
                  aCML, RARS-T or MDS/MPN-U) which warrants treatment. Patients with these
                  diagnoses may be eligible, provided they are able to obtain ruxolitinib from
                  commercial supply.

               -  patients who have not yet received therapy with any JAK-STAT inhibitory agents or
                  patients on at least 8 weeks of a steady dose of ruxolitinib; patients with
                  exposure to other JAK-STAT inhibitory agents are not eligible.

          -  A bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1
             treatment to establish the baseline fibrosis score, and consent is required prior to
             that bone marrow biopsy to assure tissue is collected for protocol mandated testing;

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
             0-2;

          -  Life expectancy of at least six months;

          -  Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments,
             excluding alopecia and anemia/thrombocytopenia assessed to be related to Ruxolitinib
             exposure;

          -  Women of child bearing potential (WCBP), defined as a sexually mature woman not
             surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤55
             years or 12 months if >55 years, must have a negative serum pregnancy test within 72
             hours prior to the first dose of study drug and must agree to use highly effective
             methods of birth control throughout the study. Highly effective methods of
             contraception include total abstinence, sterilization of patient and/or patient's
             partner, or use of combination of two methods, including barrier methods (double
             barrier method is acceptable), IUD or IUS, and hormonal implants or combined oral
             contraceptives

          -  Must have adequate organ function as demonstrated by the following:

          -  ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN), or ≤ 4 x ULN (if upon
             judgment of the treating physician, it is believed to be due to extramedullary
             hematopoiesis [EMH] related to MF); Total bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN (if upon
             judgment of the treating physician, it is believed to be due to EMH related to MF);
             Serum creatinine ≤ 2.5 mg/dL x ULN; Hgb ≥ 8 g/dL; Plt ≥ 30k; ANC ≥ 750/uL

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from trial entry:

          -  Other invasive malignancies within the last 2 years, except non-melanoma skin cancer
             and localized cured prostate, cervical cancer, and DCIS

          -  History of cerebral vascular accident, unstable angina, myocardial infarction, or
             ventricular arrhythmia within the last 6 months;

          -  Any serious, unstable medical or psychiatric condition that would prevent, (as judged
             by the Investigator) the subject properly providing informed consent or any condition
             which would jeopardize compliance with the protocol

          -  Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B,
             or C infection (hepatitis B carriers with normal LFTs and undetectable viral loads are
             allowed);

          -  Organ transplant recipients other than bone marrow transplant;

          -  Women who are pregnant or lactating;

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic
             stem cell transplant within 6 months. Grade II, or greater, active graft versus-host
             disease.

          -  Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter)
             prior to the first dose of TGR-1202. For investigational drugs for which 5 half-lives
             is less than 21 days, a minimum of 10 days between termination of the investigational
             drug and administration of TGR-1202 is required.

          -  Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically
             inhibits PI3K or mTOR within last 6 months;

          -  Any major surgery, chemotherapy, or immunotherapy within the last 21 days (limited
             palliative radiation is allowed ≥ 2 weeks); concurrent hydroxyurea is allowed if less
             than 2 grams daily and on stable dose for ≥14 days prior to study entry;

          -  Patient has received wide field radiotherapy (including therapeutic radioisotopes such
             as strontium 89) ≤ 28 days or limited field radiation for palliation ≤ 14 days prior
             to starting trial medications or has not recovered from side effects of such therapy;

          -  Ongoing immunosuppressive therapy (prednisone or equivalent ≤10 mg daily allowed as
             clinically warranted). Patients are allowed to use topical or inhaled corticosteroids;

          -  Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol

          -  Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol.